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Meeting report: 2nd meeting of the European Thoracic Oncology Platform (ETOP) 
 
Rolf Stahel, Paul Baas, Corinne Faivre-Finn, Christophe Dooms, Bernward Passlick, Julien 
Mazières, Federico Cappuzzo, Martin Früh, Jens Benn Sorenson, Fiona Blackhall, Miquel 
Taron, Cesare Gridelli, Ken O’Byrne, and Rafael Rosell 
 
The foundation of ETOP 
 
In Europe, a renewed interest in promoting and improving collaboration in clinical and 
translational research in lung cancer has emerged. Many investigators, representing 
collaborative study groups and institutions, are trying to find new ways to improve 
dissemination of knowledge and expertise in the field of rapidly evolving customized therapy. 
To accomplish this goal, discussions with European investigators during one of the thoracic 
oncology meetings in Dublin (BTOG) were initiated in early 2008. During the second 
meeting in April 2008 in Geneva, the decision was made that a formal structure was required 
to achieve this goal. Rolf Stahel from Switzerland and Paul Baas from the Netherlands took 
the initiative to prepare a draft for a foundation based on the model of the International Breast 
Cancer Study Group. The idea of the European Thoracic Oncology Platform (ETOP) was 
constructed and presented to representatives of European collaborative groups and trial 
institutions in September 2008 at the ESMO meeting in Stockholm. During this 1st ETOP 
meeting the ideas were accepted, suggestions for members of foundation council were made, 
and the collection of funds by interested groups and institutions agreed on. A first meeting of 
the ETOP foundation council including Rolf Sahel, Paul Baas, Cesare Gridelli, Ken O’Byrne 
and Rafael Rosell took place in January 2009 in Dublin during the BTOG meeting. In March 
2009 the foundation, seated in Bern, Switzerland, was approved by the authorities. 
Since then, 29 collaborative groups and trial institutions have joined ETOP, representing most 
European Countries (Figure 1) The ETOP website (www.ETOP.ch) has been activated. 
 
2nd ETOP meeting 
 
In November 2009 a second ETOP meeting was held in Zürich. There were 45 participants 
representing 21 different groups or institutions. Individual groups presented their ongoing 
trials or trial ideas. In 4 workshops themes of common interest were elaborated and 
summarized. 
 ETOP Multimodality Working Group, chaired by Corinne Faivre-Finn, Christophe 
Dooms and Bernward Passlick 
 
The Multimodality Working Group (MMWG) discussed the treatment of locally advanced 
non-small cell lung cancer (NSCLC) including combined chemo-radiotherapy (CTRT) 
treatments in unresectable disease and the role of surgery in resectable disease. The clinical 
trials in locally advanced NSCLC from the various research group members of ETOP were 
reviewed and it was noted that a number of them are accruing very slowly and are in danger 
of closing early due to poor accrual. 
 
Concurrent CTRT is recognised to be superior to sequential CTRT in selected patients with 
unresectable locally advanced NSCLC. However the group agreed that there is not an 
established standard concurrent CTRT regimen in Europe. Neither the addition of induction 
nor consolidation CT to concurrent CTRT has led to improvements in survival in unresectable 
locally advanced NSCLC. A number of unanswered questions were identified in this group of 
patients: 
1. Can we optimise the combination of CT and RT? 
 What RT? (dose escalation, acceleration, iso-toxic or dose adapted RT?) 
 What chemotherapy concurrently with RT? 
 Are 2 or 3 cycles of CT concurrently with RT sufficient? 
 Is there a role for induction or consolidation CT? 
 Is concurrent CTRT a treatment option for elderly patients? 
2. Can we identify patients likely to benefit from CTRT? 
3. What is the role of novel therapies in locally advanced NSCLC? 
 
To establish a standard of care in patients with unresectable, locally advanced NSCLC, the 
pre-requisites of such a study were discussed. A number of challenges were identified: 
selection of a control arm; RT quality assurance; the feasibility of starting concurrent CTRT 
upfront (without induction CT) in Europe and the choice of relevant endpoints. The group 
acknowledged that the impact of new treatment strategies in the context of concurrent CTRT, 
such as advanced RT techniques and targeted therapies, will be difficult to evaluate in the 
future in the absence of an established standard treatment in this group of patients. 
To evaluate the impact of induction versus consolidation chemotherapy, the group proposed a 
phase II/III trial. The first step would consist of a randomised phase II, three arm, trial 
comparing concurrent CTRT alone (control) to induction CT followed by CTRT and to 
concurrent CTRT followed by consolidation CT. The choice of the induction or consolidation 
CT in the 2 experimental arms would be based on histology. Based on feasibility and toxicity 
endpoints one of the two experimental arms would be dropped leading to a two arm phase III 
study. The group proposed not to have an upper age limit in this study to obtain data on the 
feasibility and toxicity of concurrent CTRT in the elderly patients. Some members of the 
group were of the view that a pragmatic phase III trial comparing concurrent CTRT alone 
(control) to induction CT followed by CTRT (experimental) would be relevant (and less 
complex) as in most European centres induction CT is routinely used for logistic reasons. The 
impact of the addition of induction CT is not well known as the only phase III trial comparing 
induction chemotherapy to no induction used taxol-carboplatin and this was felt to be a 
suboptimal regimen. 
To be successful, a phase III trial in patients with unresectable, locally advanced, NSCLC 
would have to be conducted in collaboration with a number of European Lung Cancer 
research groups. 
 
The role of surgery in patients with stage III NSCLC with mediastinal node involvement is 
not well established outside clinical trials. However, the members of the group agreed that 
there is a potential role for surgery. The reported studies, so far, represent non homogenous 
disease groups which makes it difficult to interpret the data and to put them in a clinical 
context. Stage IIIA-N2 NSCLC has traditionally been divided into 4 subgroups based on the 
tests that are necessary to detect N2 disease: a subgroup with N2 involvement only found on 
final pathologic examination (IIIA-1); a subgroup with intra-operatively found N2 
involvement after a preceding negative invasive mediastinal staging (IIIA-2); a large 
subgroup of patients with resectable, discrete, clinical N2 involvement proven with invasive 
mediastinal staging (IIIA-3); a subgroup of bulky unresectable N2 involvement at imaging 
(IIIA-4). The R0 resection rate within the different randomised controlled trials published so 
far reflects the diverse disease groups studied. The EORTC 08941 trial included unresectable 
stage IIIA-N2 NSCLC and aimed at making the disease resectable after induction 
chemotherapy. However, only 50% of patients with an objective response after induction 
chemotherapy underwent an R0 resection. In contrast, the INT 0139 trial demonstrated that a 
R0 resection could be obtained in 88% of patients with resectable stage IIIA-N2 NSCLC with 
objective disease control after induction therapy. The German Lung Cancer Cooperative 
Group (GLCCG) trial included (marginally) resectable stage IIIA and selected stage IIIB 
NSCLC patients with an intermediate R0 resection rate of 55-69% after induction therapy8. 
As the R0 resection rate is an important prognostic factor, the group felt that a clear definition 
of resectability would be valuable. A number of additional unanswered questions were 
identified in the group: 
1. Trial design : 
a. Do we consider an upfront randomisation and thus ‘one fits all’ design, e.g. a 
surgical arm versus a chemo radiotherapy arm. 
b. Do we consider restaging after induction therapy in order to ‘identify patients’ 
likely to benefit from a radical combined modality approach before 
randomisation between a surgical arm and a chemo-radiotherapy arm. 
2. Which patients are candidates for surgical resection: only patients requiring lobectomy 
or also selected patients requiring pneumonectomy? 
3. Which type of induction therapy (induction chemotherapy or induction chemo 
radiotherapy) results in the best survival benefit or local disease control? 
4. Which is the optimal sequence of treatment modalities (Surgery/Radiotherapy/ 
Chemotherapy) in single level or single zone N2? 
 
During the discussion, the members of the group showed interest in two types of trials. First, a 
phase II trial focussing on restaging after an induction therapy gained interest as this could 
potentially identify those patients who really benefit from a subsequent radical curative 
treatment. This phase II trial may precede a phase III trial focussing on two different 
subsequent radical treatment modalities, e.g. a comparison between surgery and concurrent 
CTRT alone. Secondly, there was interest in a phase III trial proposal on primary surgical 
resection for single zone N2 disease with upfront randomisation between primary surgical 
resection with adjuvant chemotherapy and concurrent CTRT alone.  
Again the group felt that in order to be successful, a phase III trial in resectable locally 
advanced NSCLC would have to be conducted in collaboration with a number of European 
Lung Cancer research groups. In such a phase III trial, there is clearly a need for quality 
control and quality assurance both for surgical expertise and RT expertise/equipment. 
 
 
Advanced Non Small Cell Lung Cancer Working Group, chaired by Julien Mazières 
and Federico Cappuzzo 
 
We identified four strategies in stage IV NSCLC and discussed clinical trial opportunities for 
all of them.  
 
1. Optimization of standard chemotherapy by integrating biomarkers in drug selection. 
Clinical trials are ongoing based on BRCA1 expression (BREC study, Spanish Lung Cancer 
Group), on ERCC1 expression (ET Trial, London Lung Cancer Group), ERCC1, BRCA1 and 
RRM1 (HORG trial). Recruitment in these trials is often low. The group suggests that ETOP 
may help in sharing expertise for biomarker analysis and in connecting groups together to 
facilitate patients accrual. 
 
2. Combination of a third agent with standard chemotherapy. 
Many ongoing trials are testing the effect and toxicity of combining standard chemotherapy 
with a “targeted” agent (EGFR inhibitors, antiangiogenic agent). Most of these compounds 
are not freely available and require industry-sponsored studies. The group proposed that this 
trial design could be tested in NSCLC subgroups (such as IGF1-R inhibitors in squamous cell 
carcinoma).  
 
3. Front line monotherapy with “targeted” agents based on tumor biomarker in highly selected 
patients. 
The more robust biomarker currently available is mutation status of the EGFR gene. 
EURTAC trial is ongoing testing erlotinib vs. chemotherapy in mutated patients. We 
anticipate that future challenges will be the treatment of primary or secondary resistance to 
EGFR-TKI treatment in patients with active mutated EGFR genes. The subgroup of patients 
harbouring T790M mutation is of interest. A specific trial evaluating different strategies in 
these patients, as proposed by Pr R. Rosell, could be supported by ETOP in order to help for 
patient accrual. Other targets such as ALK-EML4 or Ras mutation (treated with RAF or 
MEKK inhibitors) also appear interesting. 
 
4. Maintenance therapy with a single agent after induction chemotherapy. 
Results form the recently closed IFCT-GFPC 0501 trial (observation vs erlotinib vs 
gemcitabine after 4 courses of cisplatinum-gemcitabine) are awaited for the next ASCO 
meeting. Maintenance with pazopanib is currently discussed by the EORTC. Other industry-
sponsored trials are ongoing.  
 
Specific trial in the elderly conducted by the Italian group (mono vs combination therapy), 
GFPC (treatment based on a geriatric index) and IFCT (mono vs combination therapy) are 
also ongoing. 
Specific trials in bronchiolo-alveolar carcinoma (IFCT) are also conducted (IFCT). 
 
 
Small cell lung cancer Working Group, chaired by Martin Früh and Jens Benn 
Sorenson 
 
Our working group reviewed ongoing trials in small cell lung cancer (SCLC) in Europe with a 
focus on currently recruiting ETOP trials. In addition, we had a more in depth discussion 
about a new trial proposed to ETOP by the Dublin group.  
We divided the trials into the following categories: 1) Limited disease (LD), 2) first line 
extensive disease (ED), 3) second line and 4) ongoing non-interventional SCLC trials.  
 
1. The CONVERT phase III trial in LD patients is addressing the important question of the 
radiation dose comparing 45Gy BID vs. 66Gy OD delivered concurrently with 
cisplatin/etoposide. So far 58 out of 532 patients have been enrolled. Additional centres are 
invited to participate and contact Dr. Faivre-Finn from Manchester. Careful selection of the 
centres that are able to perform the sophisticated translational research and radiotherapy part 
is critical. 
 
2. In first line ED patients the European Lung Cancer Working Party (ELCWP) is carrying 
out a phase III study comparing cisplatin/etoposide vs. etoposide/epirubicin/ifosfamide to 
demonstrate the superiority of  the cisplatin/etoposide drug combination. This trial is close to 
have completed its accrual. The contact person is Dr. Sculier from Brussels. 
Another phase III trial is run by the Danish Oncological Lung Cancer Group and compares 
cisplatin/topotecan to carboplatin/etoposide. Approximately half of the 260 patients needed 
are currently recruited. Dr Langer from Copenhagen is the principle investigator. 
A first line single arm phase II study conducted by the SAKK (SAKK 15/08, lead by Dr Früh, 
St. Gallen) will soon be opened in Switzerland and the Netherlands. Fifty seven ED patients 
without brain metastases will be enrolled investigating a new promising vascular disruptive 
agent as part of the drug combination carboplatin/paclitaxel/ASA404.  
Of most interest was Dr. O`Byrne`s proposal of a Phase II/III trial evaluating the efficacy and 
tolerability of an anti-IGF1R monoclonal antibody in combination with carboplatin/etopsoide. 
In this two-arm randomised controlled trial of carboplatin/etoposide plus the anti-IGF1R 
monoclonal antibody R1507 vs. carboplatin/etoposide plus placebo, 138 patients are needed 
for the phase II part and 928 for the consecutive phase III trial. Critical issues have been 
identified and include the question of a maintenance antibody therapy, recommendation of 
prophylactic cranial irradiation and chest irradiation, recommendations on second line 
treatment, definition of translational research with the suggestion to identify dedicated 
pathologists in each country in order to avoid shipping specimen abroad. In addition, 
reconsideration of statistical aspects was proposed in order to reduce sample size by 
increasing the targeted survival benefit in the phase III part. 
 
3. In the second line setting, a single arm phase II trial is testing the activity of 
cyclophosphamide, adriamycin, vindesin and valproic acid in refractory patients (ELCWP, 
lead by Dr. Berghmans). There is also an industry sponsored phase III trial of amrubicin 
versus topotecan currently recruiting. 
 
4. Lastly, out of the ongoing Non-interventional SCLC trials a trial of the Hellenic group 
(HOG) assessing pharmacogenomic and gene expression profiles for resistance to cisplatin, 
etoposide, topotecan was mentioned. 
 
 
Translational research Working Group, chaired by Fiona Blackhall and Miquel Taron 
 
Translational research has a wide remit spanning basic molecular mechanisms of lung cancer 
that may be exploited for early diagnosis or therapeutic control, novel treatment target 
discovery and validation, predictive and prognostic biomarker discovery and validation, and 
ultimately trials designed to test personalised approaches; so-called customised or biomarker 
driven trials. Infrastructure for translational research varies widely among centres yet 
standardised procedures and protocols are critical for clinically meaningful data from 
molecular correlative studies. The ETOP translational subgroup has a primary goal to create 
an inventory of laboratory capabilities to include technology platforms, storage and 
processing facilities, levels of laboratory accreditation, certification and capacity among its 
partners. Secondly, a manual of standard operating procedures for sample acquisition, storage 
and processing in addition to knowledge of country specific ethical considerations and 
regulatory governance for research using human samples and tissue will be generated. A 
further aim will be for ETOP partners to host and provide training workshops and quality 
assurance programs. These steps will establish a basis from which a rigorous and 
comprehensive approach to translational research can be facilitated by the ETOP network. 
Figure 1 
 
